Wockhardt Ltd 2023 AR2
The report highlights Wockhardt's strategic realignment during the fiscal year 2022-2023, including the restructuring of its US business by closing the Morton Grove facility and transitioning to contract manufacturing. The company successfully initiated the Global Phase 3 clinical study of its novel antibiotic WCK 5222 and completed patient recruitment for the Phase 3 study of WCK 4873 in India. Additionally, Wockhardt expanded its diabetes and biologicals business, targeting emerging markets. On the sustainability front, the company implemented energy-saving measures across its manufacturing sites, achieved zero liquid discharge at several plants, and continued its social initiatives through the Wockhardt Foundation, touching over 128 million lives.
Company: Wockhardt Ltd
Sector: Health Care
Country: India
Year: 2023
Type: AR2
Pages: 264
Wockhardt Ltd
Annual Report
The report highlights Wockhardt's strategic realignment during the fiscal year 2022-2023, including the restructuring of its US business by closing the Morton Grove facility and transitioning to contract manufacturing. The company successfully initiated the Global Phase 3 clinical study of its novel antibiotic WCK 5222 and completed patient recruitment for the Phase 3 study of WCK 4873 in India. Additionally, Wockhardt expanded its diabetes and biologicals business, targeting emerging markets. On the sustainability front, the company implemented energy-saving measures across its manufacturing sites, achieved zero liquid discharge at several plants, and continued its social initiatives through the Wockhardt Foundation, touching over 128 million lives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees